Ushering in the next generation of cancer detection and treatment
Transforming patient care through continuous collaboration and innovation
Renovaro and its subsidiaries – Renovaro Cube, Renovaro Bio, and BioSymetrics – are working together to revolutionize how cancer is detected and treated, transforming the future of oncology.
Renovaro’s subsidiaries work collaboratively, leveraging their expertise in early diagnosis, drug development, patient stratification,
and treatment selection.
and treatment selection.
Our collaborative approach extends beyond the Renovaro family, as we actively engage in partnerships with clinics, hospitals, and research partners throughout the U.S. and Europe.
Why choose Renovaro?
Your partner in AI-driven transformation, offering unparalleled expertise, tailored solutions, ethical practices, and a commitment to boosting efficiency and productivity in your business.
The Renovaro ecosystem
Your partner in AI-driven transformation, offering unparalleled expertise, tailored solutions, ethical practices, and a commitment to boosting efficiency and productivity in your business.
01. Detect
Building the bridge between artificial intelligence and cancer diagnostics.
Renovaro Cube leverages deep learning and multi-omic integration to develop advanced liquid biopsy models for early cancer detection. By making non-invasive, routine screening the new standard in cancer care, we empower healthcare providers with actionable insights for life-saving, timely interventions.
02. Discover
Pioneering therapeutic cancer vaccines to overcome tumor immune evasion.
RenovaroBio develops cutting-edge cell, gene, and immunotherapy platforms that restore the body's natural ability to fight cancer and infectious diseases. By genetically modifying allogenic dendritic cells, we are developing therapeutic vaccines that overcome tumor immune evasion and drive more effective tumor eradication.
03. Predict
Predicting treatment efficacy through machine learning.
Renovaro accelerates the development of precision medicines, using machine learning, to effectively treat individuals based on their distinct diagnosis and genetic profile, increasing chances of clinical success.
04. De-risk
Validating in-silico predictions with in-vivo experiments.
BioSymetrics' phenomics-driven drug discovery platform leverages genotype-phenotype predictions to translate between experiments in model systems and human phenotypic effects. Drug effect predictions made in-silico using the proprietary Contingent AI platform are validated in zebrafish – a model organism genetically similar to humans. Effects observed in model organisms are used to make predict effects on human phenotype.
We believe that with great technology comes great responsibility. Ethical considerations are integral to our AI development process.
Our AI solutions are transforming healthcare, finance, manufacturing, and more, making processes smarter, operations more efficient, and decision-making more insightful. We empower businesses to harness the potential of AI, driving growth and innovation in an increasingly digital world. We're committed to creating AI that respects privacy, ensures fairness, and operates transparently, paving the way for a future
84%
Accuracy in machine learning models
3Billion
Data points processed daily by our systems
60+
Patents filed in various
AI technologies
42PB
Of data is stored in our systems
